PBYI News and Press, Puma Biotechnology Inc From 08/04/22

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2022. Unless otherwise stated, all comparisons are for the second quarter of 2022 compared to the second quarter of 2021. Product revenue, net cons...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented results from the Phase II SUMMIT trial, assessing the efficacy of combined neratinib, fulvestrant, and trastuzumab in patients with hormone receptor positive, HER2-negative, HER2 -mutant metastatic breas...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented final results from the Phase II SUMMIT ‘basket’ trial, assessing the efficacy of neratinib in treatment-refractory patients with metastatic biliary tract cancers with somatic HER2 mutations...

Bluebird Bio (BLUE), Clovis Oncology (NASDAQ:CLVS) and Chimerix (CMRX) are trading lower in the morning hours Thursday after Truist said that the three biotechs are at the risk of running out of cash within the next six months. The analysis of 118 companies developing cancer medications exclu...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the publication of two abstracts on neratinib to be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. The ASCO Annual Meeting will be held in person at McCormick Place in Chi...

The following slide deck was published by Puma Biotechnology, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Puma Biotechnology, Inc. 2022 Q1 - Results - Earnings Call Presentation

Puma Biotechnology, Inc. (PBYI) Q1 2022 Earnings Conference Call May 5, 2022 16:30 ET Company Participants Mariann Ohanesian - Senior Director of Investor Relations Alan Auerbach - Chairman, President & Chief Executive Officer Jeff Ludwig - Chief Commercial Officer Maximo Nougues - Chief ...

Puma Biotechnology press release (NASDAQ:PBYI): Q1 Non-GAAP EPS of -$0.01 beats by $0.10. Revenue of $45.7M beats by $0.63M. For further details see: Puma Biotechnology Non-GAAP EPS of -$0.01 beats by $0.10, revenue of $45.7M beats by $0.63M

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2022. Unless otherwise stated, all comparisons are for the first quarter of 2022 compared to the first quarter of 2021. Product revenue, net consis...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the release of titles of abstracts on neratinib to be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. The ASCO Annual Meeting will be held at McCormick Place in Chicago and...